ILEX Oncology Services Acquires U.S. Operations of British Biotech Maryland Office and Staff Expand East Coast Presence
SAN ANTONIO and OXFORD, England, Mar 2, 2000 /PRNewswire via COMTEX/ --
ILEX(TM) Oncology Services, Inc., and British Biotech plc (Nasdaq: BBIOY) today
announced the signing of an agreement under which ILEX acquired the operations
of British Biotech's Annapolis, Maryland office.
Under the terms of the agreement, ILEX has acquired the Annapolis facility and
will provide contracted drug development services necessary to complete the
ongoing clinical development of marimastat for British Biotech in North America.
Marimastat is currently being investigated in seven Phase III studies designed
to assess the compound's potential to slow the progression of a range of solid
tumors and improve patient survival.
"In addition to an important series of contracted projects and an already
established workforce, this acquisition will allow us to interact more
effectively with our East Coast-based customers," said Michael T. Dwyer,
president of ILEX Oncology Services. "It provides closer proximity to regulatory
agencies and many of our clinical investigators. We believe that these elements
will create cost efficiencies that can be passed along to the pharmaceutical and
biotech companies utilizing our services."
The chief executive of British Biotech, Dr. Elliot Goldstein, said, "This
agreement furthers the Company's strategy of creating strong partnerships and
ensuring clinical development is conducted in an efficient and cost effective
manner. ILEX's commitment to and focus on oncology products makes this an ideal
relationship for British Biotech."
Following the agreement, management of the Maryland facility will be under the
direction of Kathleen Heck, vice president of clinical operations at ILEX. Heck
joined ILEX in 1995 and has directed client services and project management of
many of the pre-clinical and clinical studies for ILEX customers. She most
recently served as director of business development.
ILEX Oncology Services, Inc. is a wholly owned subsidiary of ILEX Oncology, Inc.
(Nasdaq: ILXO), a drug development company focused predominantly on accelerated
development of drugs for the treatment and prevention of cancer. The company
does this in two ways: by offering drug development services on a contract basis
to pharmaceutical and biotech companies through its ILEX Oncology Services
subsidiary and by advancing a diversified portfolio of anticancer drugs through
its ILEX Products subsidiary. These complementary businesses draw from the
company's core expertise: relationships with international oncology experts,
strategic alliances that provide unparalleled access to patient recruitment for
clinical trials, and simultaneous European and US drug development and approval
capabilities.
More information on ILEX Oncology, Inc. can be accessed on the World Wide Web at
www.ilexoncology.com.
British Biotech is a research and development-stage pharmaceutical company based
in Oxford, UK, which is developing drugs for the treatment of unmet medical
needs such as cancer and inflammatory and infectious diseases. The main
technology platform is inhibition of metalloenzymes which will be supplemented
through the addition of externally-generated programs.
Additional information on British Biotech may be found on the Internet at
www.britishbiotech.com.
Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because such statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include, but are
not limited to, the early stage of the companies' compounds under development;
risks in technology and product development; failure to successfully complete
clinical trials; failure to receive market clearance from regulatory agencies;
dependence on third parties and partners and those risks described in the Form
S-3 filed by ILEX Oncology, Inc. on January 7, 2000 (Commission file
#333-95353), the ILEX Annual Report on Form 10-K for the year ended December 31,
1998, in filings made by ILEX with the SEC and those in the British Biotech plc
Annual Report dated April 30, 1999. The companies disclaim any obligation to
update these forward-looking statements.
Contact:
Connie Wierman, Business Dev., ILEX Oncology Services, Inc., 210-949-8233
Ann Stevens, Investor Relations, ILEX Oncology, Inc., 210-949-8230
Deborah Sibley, Sibley & Associates Communications, 210-497-3250
Tony Weir, British Biotech plc, 011 44 1865-781166
Gerard Coffey, G A Kraut Company, 212-696-5600
SOURCE ILEX Oncology, Inc.
(C) 2000 PR Newswire. All rights reserved.
www.prnewswire.com
CONTACT: Connie Wierman, Business Dev. of ILEX Oncology Services, Inc.,
210-949-8233; or Ann Stevens, Investor Relations of ILEX Oncology, Inc.,
210-949-8230; or Deborah Sibley of Sibley & Associates Communications,
210-497-3250; or Tony Weir of British Biotech plc, 011 44 1865-781166; or
Gerard Coffey of G A Kraut Company, 212-696-5600
KEYWORD: Texas
Maryland
England
INDUSTRY KEYWORD: HEA
MTC
SUBJECT CODE: TNM
URL: www.britishbiotech.com
SAN ANTONIO and OXFORD, England, Mar 2, 2000 /PRNewswire via COMTEX/ --
ILEX(TM) Oncology Services, Inc., and British Biotech plc (Nasdaq: BBIOY) today
announced the signing of an agreement under which ILEX acquired the operations
of British Biotech's Annapolis, Maryland office.
Under the terms of the agreement, ILEX has acquired the Annapolis facility and
will provide contracted drug development services necessary to complete the
ongoing clinical development of marimastat for British Biotech in North America.
Marimastat is currently being investigated in seven Phase III studies designed
to assess the compound's potential to slow the progression of a range of solid
tumors and improve patient survival.
"In addition to an important series of contracted projects and an already
established workforce, this acquisition will allow us to interact more
effectively with our East Coast-based customers," said Michael T. Dwyer,
president of ILEX Oncology Services. "It provides closer proximity to regulatory
agencies and many of our clinical investigators. We believe that these elements
will create cost efficiencies that can be passed along to the pharmaceutical and
biotech companies utilizing our services."
The chief executive of British Biotech, Dr. Elliot Goldstein, said, "This
agreement furthers the Company's strategy of creating strong partnerships and
ensuring clinical development is conducted in an efficient and cost effective
manner. ILEX's commitment to and focus on oncology products makes this an ideal
relationship for British Biotech."
Following the agreement, management of the Maryland facility will be under the
direction of Kathleen Heck, vice president of clinical operations at ILEX. Heck
joined ILEX in 1995 and has directed client services and project management of
many of the pre-clinical and clinical studies for ILEX customers. She most
recently served as director of business development.
ILEX Oncology Services, Inc. is a wholly owned subsidiary of ILEX Oncology, Inc.
(Nasdaq: ILXO), a drug development company focused predominantly on accelerated
development of drugs for the treatment and prevention of cancer. The company
does this in two ways: by offering drug development services on a contract basis
to pharmaceutical and biotech companies through its ILEX Oncology Services
subsidiary and by advancing a diversified portfolio of anticancer drugs through
its ILEX Products subsidiary. These complementary businesses draw from the
company's core expertise: relationships with international oncology experts,
strategic alliances that provide unparalleled access to patient recruitment for
clinical trials, and simultaneous European and US drug development and approval
capabilities.
More information on ILEX Oncology, Inc. can be accessed on the World Wide Web at
www.ilexoncology.com.
British Biotech is a research and development-stage pharmaceutical company based
in Oxford, UK, which is developing drugs for the treatment of unmet medical
needs such as cancer and inflammatory and infectious diseases. The main
technology platform is inhibition of metalloenzymes which will be supplemented
through the addition of externally-generated programs.
Additional information on British Biotech may be found on the Internet at
www.britishbiotech.com.
Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because such statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include, but are
not limited to, the early stage of the companies' compounds under development;
risks in technology and product development; failure to successfully complete
clinical trials; failure to receive market clearance from regulatory agencies;
dependence on third parties and partners and those risks described in the Form
S-3 filed by ILEX Oncology, Inc. on January 7, 2000 (Commission file
#333-95353), the ILEX Annual Report on Form 10-K for the year ended December 31,
1998, in filings made by ILEX with the SEC and those in the British Biotech plc
Annual Report dated April 30, 1999. The companies disclaim any obligation to
update these forward-looking statements.
Contact:
Connie Wierman, Business Dev., ILEX Oncology Services, Inc., 210-949-8233
Ann Stevens, Investor Relations, ILEX Oncology, Inc., 210-949-8230
Deborah Sibley, Sibley & Associates Communications, 210-497-3250
Tony Weir, British Biotech plc, 011 44 1865-781166
Gerard Coffey, G A Kraut Company, 212-696-5600
SOURCE ILEX Oncology, Inc.
(C) 2000 PR Newswire. All rights reserved.
www.prnewswire.com
CONTACT: Connie Wierman, Business Dev. of ILEX Oncology Services, Inc.,
210-949-8233; or Ann Stevens, Investor Relations of ILEX Oncology, Inc.,
210-949-8230; or Deborah Sibley of Sibley & Associates Communications,
210-497-3250; or Tony Weir of British Biotech plc, 011 44 1865-781166; or
Gerard Coffey of G A Kraut Company, 212-696-5600
KEYWORD: Texas
Maryland
England
INDUSTRY KEYWORD: HEA
MTC
SUBJECT CODE: TNM
URL: www.britishbiotech.com
